Europe Interstitial Cystitis Market - Industry Trends and Forecast to 2029

Description

List of Tables

The Europe interstitial cystitis market is projected to register a substantial CAGR of 9.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.

Market Segmentation:

By Severity (Mild to Moderate and Moderate to Severe), Treatment Type (Medications, Bladder Instillations, Botulinum Toxin A, Nerve Stimulation and Surgery), Route of Administration (Oral, Parenteral, Intravesical, Topical, and Others), Mode of Purchase (Over The Counter and Prescription), Patient Type (Pediatric and Adults), End User (Hospitals, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe), Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Europe interstitial cystitis market are:

Increase prevalence of interstitial cystitis
Rise in product approvals

Market Players:

Some of the major players operating in the Europe interstitial cystitis market are:

Hikma Pharmaceuticals
Sandoz AG
Sun Pharmaceutical Industries Ltd.
Lannett
Pfizer, Inc.
Strides Pharma Science Limited
Aurobindo Pharma USA
Dr. Reddy's Laboratories, Inc.
Teva Pharmaceuticals, Inc.
Johnson& Johnson Services, Inc.
Bayer AG
Reckitt Benckiser Group PLC

1 INTRODUCTION 57

1.1 OBJECTIVES OF THE STUDY 57
1.2 MARKET DEFINITION 57
1.3 OVERVIEW OF EUROPE INTERSTITIAL CYSTITIS MARKET 57
1.4 LIMITATIONS 58
1.5 MARKETS COVERED 59

2 MARKET SEGMENTATION 61

2.1 MARKETS COVERED 61
2.2 GEOGRAPHICAL SCOPE 62
2.3 YEARS CONSIDERED FOR THE STUDY 63
2.4 CURRENCY AND PRICING 63
2.5 DBMR TRIPOD DATA VALIDATION MODEL 64
2.6 MULTIVARIATE MODELLING 67
2.7 TYPE LIFELINE CURVE 67
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
2.9 DBMR MARKET POSITION GRID 69
2.10 MARKET APPLICATION COVERAGE GRID 70
2.11 VENDOR SHARE ANALYSIS 71
2.12 SECONDARY SOURCES 72
2.13 ASSUMPTIONS 72

3 EXECUTIVE SUMMARY 73

4 PREMIUM INSIGHTS 75

4.1 PESTEL ANALYSIS 76
4.2 PORTER'S FIVE FORCES 77
4.3 PIPELINE ANALYSIS FOR INTERSTITIAL CYSTITIS TREATMENT MARKET 78
4.4 EPIDEMIOLOGY 79

5 EUROPE INTERSTITIAL CYSTITIS MARKET: REGULATIONS 80

5.1 FOOD AND DRUG ADMINISTRATION (FDA) GUIDELINES 80
5.2 EUROPEAN MEDICINES AGENCY (EMA) GUIDELINES 81
5.3 JAPAN REGULATORY GUIDANCE 82

6 MARKET OVERVIEW 83

6.1 DRIVERS 85
- 6.1.1 INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC) 85
- 6.1.2 RISE IN HEALTHCARE EXPENDITURE 85
- 6.1.3 STRATEGIC INITIATIVES OF KEY PLAYERS 86
- 6.1.4 INCREASE IN R&D EFFORTS IN THE HEALTHCARE INDUSTRY 86
- 6.1.5 RISING DISEASE MANAGEMENT PROGRAMS 86
6.2 RESTRAINTS 87
- 6.2.1 HIGH COST OF TREATMENT OF INTERSTITIAL CYSTITIS 87
- 6.2.2 LACK OF AWARENESS ABOUT BLADDER DISORDERS-RELATED PROBLEMS 87
- 6.2.3 DEARTH OF SKILLED PROFESSIONALS 88
6.3 OPPORTUNITIES 88
- 6.3.1 FAVORABLE REIMBURSEMENT SCENARIO 88
- 6.3.2 INCREASE IN DRUG APPROVALS AND LAUNCHES 89
- 6.3.3 IMPROVING HEALTHCARE SYSTEM 89
- 6.3.4 COMBINATION OF DIFFERENT TARGET THERAPIES 89
6.4 CHALLENGES 90
- 6.4.1 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL 90
- 6.4.2 PATENT EXPIRY OF DRUGS 91

7 EUROPE INTERSTITIAL CYSTITIS MARKET, BY SEVERITY 92

7.1 OVERVIEW 93
7.2 MILD TO MODERATE 96
7.3 MODERATE TO SEVERE 96

8 EUROPE INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE 97

8.1 OVERVIEW 98
8.2 MEDICATIONS 101
- 8.2.1 ANALGESICS 101
  - 8.2.1.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 102
    - 8.2.1.1.1 IBUPROFEN 102
    - 8.2.1.1.2 NAPROXEN 102
    - 8.2.1.1.3 OTHERS 102
  - 8.2.1.2 ACETAMINOPHEN 102
  - 8.2.1.3 NON-NARCOTIC PAIN MEDICATION 102
    - 8.2.1.3.1 METHENAMINE 103
    - 8.2.1.3.2 PHENAZOPYRIDINE 103
    - 8.2.1.3.3 OTHERS 103
  - 8.2.1.4 NARCOTIC PAIN MEDICATION 103
    - 8.2.1.4.1 CODEINE 104
    - 8.2.1.4.2 HYDROCODONE 104
    - 8.2.1.4.3 OXYCODONE 104
    - 8.2.1.4.4 OXYMORPHONE 104
    - 8.2.1.4.5 MORPHINE 104
    - 8.2.1.4.6 HYDROMORPHONE 104
    - 8.2.1.4.7 METHADONE 105
    - 8.2.1.4.8 OTHERS 105
- 8.2.2 ANTIHISTAMINES 105
  - 8.2.2.1 LORATADINE 105
  - 8.2.2.2 HYDROXYZINE 105
  - 8.2.2.3 OTHERS 105
- 8.2.3 TRICYCLIC ANTIDEPRESSANTS 105
  - 8.2.3.1 AMITRIPTYLINE 106
  - 8.2.3.2 IMIPRAMINE 106
  - 8.2.3.3 OTHERS 106
- 8.2.4 IMMUNOSUPPRESSANTS 106
  - 8.2.4.1 CYCLOSPORINE 106
  - 8.2.4.2 MYCOPHENOLATE 106
  - 8.2.4.3 OTHERS 107
- 8.2.5 PENTOSAN POLYSULFATE SODIUM 107
- 8.2.6 OTHERS 107
  - 8.2.6.1 ALPHA BLOCKERS 107
    - 8.2.6.1.1 DOXAZOSIN 108
    - 8.2.6.1.2 TERAZOSIN 108
    - 8.2.6.1.3 TAMSULOSIN 108
    - 8.2.6.1.4 OTHERS 108
  - 8.2.6.2 AMPHETAMINES 108
  - 8.2.6.3 LEUKOTRIENE INHIBITORS 108
    - 8.2.6.3.1 MONTELUKAST 109
    - 8.2.6.3.2 ZAFIRLUKAST 109
    - 8.2.6.3.3 OTHERS 109
  - 8.2.6.4 OTHERS 109
8.3 BLADDER INSTILLATIONS 109
- 8.3.1 DIMETHYL SULFOXIDE 110
- 8.3.2 HEPARIN 110
- 8.3.3 OTHERS 110
8.4 BOTULINUM TOXIN A 110
8.5 SURGERY 111
- 8.5.1 FULGURATION 111
- 8.5.2 RESECTION 111
- 8.5.3 BLADDER AUGMENTATION 111
8.6 NERVE STIMULATIONS 111

9 EUROPE INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION 113

9.1 OVERVIEW 114
9.2 ORAL 117
- 9.2.1 TABLETS 117
  - 9.2.1.1 EXTENDED RELEASE 118
  - 9.2.1.2 IMMEDIATE RELEASE 118
- 9.2.2 CAPSULES 118
- 9.2.3 OTHERS 118
9.3 PARENTERAL 118
9.4 INTRAVESICAL 119
9.5 TOPICAL 119
9.6 OTHERS 120

10 EUROPE INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE 121

10.1 OVERVIEW 122
10.2 OVER THE COUNTER 125
10.3 PRESCRIPTION 125

11 EUROPE INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE 126

11.1 OVERVIEW 127
11.2 ADULTS 130
11.3 PEDIATRIC 130

12 EUROPE INTERSTITIAL CYSTITIS MARKET, BY END USER 131

12.1 OVERVIEW 132
12.2 HOSPITALS 135
12.3 CLINICS 135
12.4 HOME HEALTHCARE 136
12.5 OTHERS 136

13 EUROPE INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL 137

13.1 OVERVIEW 138
13.2 DIRECT TENDER 141
13.3 RETAIL SALES 141
- 13.3.1 PHARMACY STORES 142
- 13.3.2 ONLINE RETAIL CHANNEL 142
- 13.3.3 OTHERS 142
13.4 OTHERS 142

14 EUROPE INTERSTITIAL CYSTITIS MARKET, BY GEOGRAPHY 143

14.1 EUROPE 144
- 14.1.1 GERMANY 155
- 14.1.2 U.K. 161
- 14.1.3 FRANCE 167
- 14.1.4 ITALY 173
- 14.1.5 SPAIN 179
- 14.1.6 TURKEY 185
- 14.1.7 RUSSIA 191
- 14.1.8 NETHERLANDS 197
- 14.1.9 SWITZERLAND 203
- 14.1.10 BELGIUM 209
- 14.1.11 REST OF EUROPE 215

15 EUROPE INTERSTITIAL CYSTITIS MARKET: COMPANY LANDSCAPE 216

15.1 COMPANY SHARE ANALYSIS: EUROPE 216

16 SWOT ANALYSIS 217

17 COMPANY PROFILE 218

17.1 TEVA PHARMACEUTICALS INDUSTRIES LTD. 218
- 17.1.1 COMPANY SNAPSHOT 218
- 17.1.2 REVENUE ANALYSIS 218
- 17.1.3 PRODUCT PORTFOLIO 219
- 17.1.4 RECENT DEVELOPMENTS 219
17.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG) 220
- 17.2.1 COMPANY SNAPSHOT 220
- 17.2.2 REVENUE ANALYSIS 220
- 17.2.3 COMPANY SHARE ANALYSIS 221
- 17.2.4 PRODUCT PORTFOLIO 221
- 17.2.5 RECENT DEVELOPMENT 221
17.3 HIKMA PHARMACEUTICALS PLC 222
- 17.3.1 COMPANY SNAPSHOT 222
- 17.3.2 REVENUE ANALYSIS 222
- 17.3.3 COMPANY SHARE ANALYSIS 223
- 17.3.4 PRODUCT PORTFOLIO 223
- 17.3.5 RECENT DEVELOPMENTS 223
17.4 DR. REDDY'S LABORATORIES LTD 224
- 17.4.1 COMPANY SNAPSHOT 224
- 17.4.2 REVENUE ANALYSIS 224
- 17.4.3 COMPANY SHARE ANALYSIS 225
- 17.4.4 PRODUCT PORTFOLIO 225
- 17.4.5 RECENT DEVELOPMENT 226
17.5 BAYER AG 227
- 17.5.1 COMPANY SNAPSHOT 227
- 17.5.2 REVENUE ANALYSIS 227
- 17.5.3 COMPANY SHARE ANALYSIS 228
- 17.5.4 PRODUCT PORTFOLIO 228
- 17.5.5 RECENT DEVELOPMENT 228
17.6 AMNEAL PHARMACEUTICAL LLC. 229
- 17.6.1 COMPANY SNAPSHOT 229
- 17.6.2 REVENUE ANALYSIS 229
- 17.6.3 PRODUCT PORTFOLIO 230
- 17.6.4 RECENT DEVELOPMENTS 230
17.7 APOTEX 231
- 17.7.1 COMPANY SNAPSHOT 231
- 17.7.2 PRODUCT PORTFOLIO 231
- 17.7.3 RECENT DEVELOPMENT 231
17.8 AUROBINDO PHARMA USA 232
- 17.8.1 COMPANY SNAPSHOT 232
- 17.8.2 REVENUE ANALYSIS 232
- 17.8.3 PRODUCT PORTFOLIO 233
- 17.8.4 RECENT DEVELOPMENT 233
17.9 AVET PHARMACEUTICALS INC. 234
- 17.9.1 COMPANY SNAPSHOT 234
- 17.9.2 PRODUCT PORTFOLIO 234
- 17.9.3 RECENT DEVELOPMENT 234
17.10 ALVOGEN 235
- 17.10.1 COMPANY SNAPSHOT 235
- 17.10.2 PRODUCT PORTFOLIO 235
- 17.10.3 10.3RECENT DEVELOPMENT 235
17.11 ACCORD-UK LTD 236
- 17.11.1 COMPANY SNAPSHOT 236
- 17.11.2 PRODUCT PORTFOLIO 236
- 17.11.3 11.3RECENT DEVELOPMENT 236
17.12 GLAXOSMITHKLINE PLC 237
- 17.12.1 COMPANY SNAPSHOT 237
- 17.12.2 12.2REVENUE ANALYSIS 237
- 17.12.3 PRODUCT PORTFOLIO 238
- 17.12.4 RECENT DEVELOPMENT 238
17.13 JOHNSON & JOHNSON SERVICES, INC. 239
- 17.13.1 COMPANY SNAPSHOT 239
- 17.13.2 REVENUE ANALYSIS 239
- 17.13.3 PRODUCT PORTFOLIO 240
- 17.13.4 RECENT DEVELOPMENT 240
17.14 LANNETT 241
- 17.14.1 COMPANY SNAPSHOT 241
- 17.14.2 REVENUE ANALYSIS 241
- 17.14.3 PRODUCT PORTFOLIO 242
- 17.14.4 RECENT DEVELOPMENT 242
17.15 PRESTIGE CONSUMER HEALTHCARE 243
- 17.15.1 COMPANY SNAPSHOT 243
- 17.15.2 REVENUE ANALYSIS 243
- 17.15.3 PRODUCT PORTFOLIO 244
- 17.15.4 RECENT DEVELOPMENTS 244
17.16 PFIZER INC. 245
- 17.16.1 COMPANY SNAPSHOT 245
- 17.16.2 REVENUE ANALYSIS 245
- 17.16.3 PRODUCT PORTFOLIO 246
- 17.16.4 RECENT DEVELOPMENT 246
17.17 RECKITT BENCKISER GROUP PLC. 247
- 17.17.1 COMPANY SNAPSHOT 247
- 17.17.2 REVENUE ANALYSIS 247
- 17.17.3 PRODUCT PORTFOLIO 247
- 17.17.4 RECENT DEVELOPMENT 248
17.18 SUN PHARMACEUTICAL INDUSTRIES LTD. 249
- 17.18.1 COMPANY SNAPSHOT 249
- 17.18.2 REVENUE ANALYSIS 249
- 17.18.3 PRODUCT PORTFOLIO 250
- 17.18.4 RECENT DEVELOPMENT 250
17.19 STRIDES PHARMA SCIENCE LIMITED. 251
- 17.19.1 COMPANY SNAPSHOT 251
- 17.19.2 REVENUE ANALYSIS 251
- 17.19.3 PRODUCT PORTFOLIO 252
- 17.19.4 RECENT DEVELOPMENT 252
17.20 VIATRIS INC. 253
- 17.20.1 COMPANY SNAPSHOT 253
- 17.20.2 REVENUE ANALYSIS 253
- 17.20.3 PRODUCT PORTFOLIO 254
- 17.20.4 RECENT DEVELOPMENT 254
17.21 VISTA PHARM INC. 255
- 17.21.1 COMPANY SNAPSHOT 255
- 17.21.2 PRODUCT PORTFOLIO 255
- 17.21.3 RECENT DEVELOPMENTS 255
17.22 ZYDUS PHARMACEUTICALS INC., 256
- 17.22.1 COMPANY SNAPSHOT 256
- 17.22.2 REVENUE ANALYSIS 256
- 17.22.3 PRODUCT PORTFOLIO 257
- 17.22.4 RECENT DEVELOPMENTS 257

18 QUESTIONNAIRE 258

19 RELATED REPORTS 261

LIST OF FIGURES

FIGURE 1 EUROPE INTERSTITIAL CYSTITIS MARKET: SEGMENTATION 32
FIGURE 2 EUROPE INTERSTITIAL CYSTITIS MARKET: DATA TRIANGULATION 35
FIGURE 3 EUROPE BLADDER DISORDERS MARKET: DROC ANALYSIS 36
FIGURE 4 EUROPE INTERSTITIAL CYSTITIS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 37
FIGURE 5 EUROPE INTERSTITIAL CYSTITIS MARKET: COMPANY RESEARCH ANALYSIS 37
FIGURE 6 EUROPE INTERSTITIAL CYSTITIS MARKET: INTERVIEW DEMOGRAPHICS 39
FIGURE 7 EUROPE INTERSTITIAL CYSTITIS MARKET: DBMR MARKET POSITION GRID 40
FIGURE 8 EUROPE INTERSTITIAL CYSTITIS MARKET: MARKET APPLICATION COVERAGE GRID 41
FIGURE 9 EUROPE INTERSTITIAL CYSTITIS MARKET: VENDOR SHARE ANALYSIS 42
FIGURE 10 EUROPE INTERSTITIAL CYSTITIS MARKET: SEGMENTATION 45
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF INTERSTITIAL CYSTITIS IS EXPECTED TO DRIVE THE EUROPE INTERSTITIAL CYSTITIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 46
FIGURE 12 MILD TO MODERATE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE INTERSTITIAL CYSTITIS MARKET IN 2022 & 2029 46
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE INTERSTITIAL CYSTITIS MARKET 55
FIGURE 14 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2021 64
FIGURE 15 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2022-2029 (USD MILLION) 65
FIGURE 16 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, CAGR (2022-2029) 65
FIGURE 17 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, LIFELINE CURVE 66
FIGURE 18 EUROPE INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2021 69
FIGURE 19 EUROPE INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION) 70
FIGURE 20 EUROPE INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, CAGR (2022-2029) 70
FIGURE 21 EUROPE INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, LIFELINE CURVE 71
FIGURE 22 EUROPE INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2021 85
FIGURE 23 EUROPE INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 86
FIGURE 24 EUROPE INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 86
FIGURE 25 EUROPE INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 87
FIGURE 26 EUROPE INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2021 93
FIGURE 27 EUROPE INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION) 94
FIGURE 28 EUROPE INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029) 94
FIGURE 29 EUROPE INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE 95
FIGURE 30 EUROPE INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2021 98
FIGURE 31 EUROPE INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION) 99
FIGURE 32 EUROPE INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, CAGR (2022-2029) 99
FIGURE 33 EUROPE INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, LIFELINE CURVE 100
FIGURE 34 EUROPE INTERSTITIAL CYSTITIS MARKET: BY END USER, 2021 103
FIGURE 35 EUROPE INTERSTITIAL CYSTITIS MARKET: BY END USER, 2022-2029 (USD MILLION) 104
FIGURE 36 EUROPE INTERSTITIAL CYSTITIS MARKET: BY END USER, CAGR (2022-2029) 104
FIGURE 37 EUROPE INTERSTITIAL CYSTITIS MARKET: BY END USER, LIFELINE CURVE 105
FIGURE 38 EUROPE INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2021 109
FIGURE 39 EUROPE INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 110
FIGURE 40 EUROPE INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 110
FIGURE 41 EUROPE INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 111
FIGURE 42 EUROPE INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021) 116
FIGURE 43 EUROPE INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021) 118
FIGURE 44 EUROPE INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029) 118
FIGURE 45 EUROPE INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029) 119
FIGURE 46 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029) 119
FIGURE 47 EUROPE INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%) 187